Back to Journals » Vascular Health and Risk Management » Volume 4 » Issue 4

Utility of ranolazine in chronic stable angina patients

Authors Arora RR

Published 8 August 2008 Volume 2008:4(4) Pages 819—824

DOI https://doi.org/10.2147/VHRM.S2841


Pawan D Patel, Rohit R Arora

Department of Cardiology, Chicago Medical School, North Chicago, IL, USA

Abstract: Chronic stable angina is a debilitating illness affecting at least 6.6 million US residents. Despite being optimally treated by pharmacotherapy and revascularization up to 26% of patients still experience angina. Diabetes mellitus is a common co-morbid condition in angina patients. Several new investigational medications are being tested for chronic angina. Advances in understanding of myocardial ischemia have prompted evaluation of a number of new antianginal strategies. In this review we discuss the utility of ranolazine, a recently approved novel antianginal agent and its efficacy in the diabetic patient population. In addition to its antianginal action in diabetic patients with chronic angina, ranolazine may have favorable effects on glycated hemoglobin levels.

Keywords: chronic stable angina, antianginal, ranolazine, diabetes mellitus, glycated hemoglobin

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]